Warning: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

UK Mid Cap strategy: Mergers and acquisitions remains a feature of the UK market

  • 13 January 2021 (5 min read)

Key points

  • The UK and European Union finalised a trade agreement
  • Hopes of global economic recovery continued following news of vaccine roll out
  • Sterling strengthened

What’s happening?

Equity markets, particularly in the UK, rose strongly in December, buoyed both by optimism related to the imminent rollout of the Pfizer and Astrazeneca Covid vaccine and news that the UK and European Union had finalised a trade agreement.

Hopes of global economic recovery continued following news of vaccine roll out, sterling strengthened, the US dollar declined and commodity prices (including oil) rose.

Towards the end of December, governments and citizens became increasingly concerned about a more contagious Covid variant (caused by a mutation on the spike protein) and this has resulted in additional ‘lock downs’ both in the UK and Internationally.

Portfolio positioning and performance

Over the month, the strategy performed strongly in absolute terms, in line with its comparative benchmark (FTSE 250 Ex Investment Trusts). From a sector perspective, the overweight position in consumer services detracted from relative performance, whereas the underweight position in financials was beneficial.

Positive stock performances of note included the holdings in Learning Technologies (a provider of e-learning services and technologies), Synairgen (a drug research company focusing on treatments for asthma and chronic obstructive pulmonary disease) and Codemasters (a developer and publisher of video games). Learning Technologies rose in December following the announcement of its acquisition of eThink Education, a leading provider of Moodle-based learning management systems. The acquisition further bolsters the company’s position in this space. Synairgen has had the all-clear from the FDA to speed up trials in the US for a treatment to be used by patients with Covid-19. The treatment is usually used by those with chronic obstructive pulmonary disease or asthma and has been shown to have efficacy against severe viral lung infections such as Covid-19. Codemasters received a bid from EA Sports.

Detractors on a relative basis included Rank, Signature Aviation (not held and received a takeover approach) and Meggitt (not held).

A new position was taken in Bytes Technology Group as part of its IPO1 . Bytes is a leading provider of world-class IT2  solutions. The Company offers a broad range services including security, storage and virtualisation, licensing, digital transformation and cloud management.


To date, the additional economic headwind caused by further Covid related ‘lockdown’ has been ignored by financial markets as investors focused more on the positive impact of vaccination and economic recovery. Bank, commodity and oil related equities have risen sharply in anticipation of both economic recovery and increasing inflation. However, economic growth remains dependent on a swift and effective roll out of the approved vaccines. In the meantime, central banks and governments remain very accommodative through direct monetary and fiscal support. It is likely that monetary policy remains accommodative for the foreseeable future.

The resolution to the protracted Brexit negotiations has helped provide support for UK Sterling and increased clarity for business. Time will further reveal both the threats and opportunities that Brexit offers.

Mergers and acquisitions remains a feature of the UK market as corporate and private equity buyers take advantage of depressed valuations.

In these times of volatile news and capital flow, we continue to focus on those companies that we believe can compound their earnings, where balance sheet strength is supportive of that growth.

No assurance can be given that the UK Mid Cap Strategy will be successful. Investors can lose some or all of their capital invested. The UK Mid Cap strategy is subject to risks including; Equity; Smaller companies risk; Liquidity risk.

  • SW5pdGlhbCBQdWJsaWMgT2ZmZXJpbmc=
  • SW5mb3JtYXRpb24gVGVjaG5vbG9neQ==

    Not for Retail distribution

    This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment.  Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. 

    Are you an IFA or other Professional Investor ?

    Are you a financial advisor, institutional, or other professional investor?

    This section is for professional investors only. You need to confirm that you have the required investment knowledge and experience to view this content. This includes understanding the risks associated with investment products, and any other required qualifications according to the rules of your jurisdiction.